Targeting CD70 in Solid Tumors: From Epigenetic Heterogeneity to Next-Generation CAR T Cell Therapies
Cancer Immuno Perspectives · 2025
DOI: 10.70996/cip.00006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immuno Perspectives, 2025. Verfasst von Lin Wang.
Abstract (Originalsprache)
This review aims to address the bottleneck of antigen heterogeneity that restricts the efficacy of chimeric antigen receptor (CAR) T cell therapy in solid tumors, with a focus on exploring the epigenetic regulatory mechanisms of CD70—a promising solid tumor target with aberrant overexpression—and developing next-generation CAR-T strategies to overcome CD70 expression heterogeneity. We comprehensively elucidate the epigenetic mechanisms underlying CD70 expression heterogeneity in solid tumors, and verify the core role of EZH2-mediated H3K27me3 modification in silencing CD70 in partial tumor cells and leading to ultra-low CD70 expression undetectable by conventional assays. Meanwhile, we analyze the limitations of conventional CD70-targeted CAR-T cells in solid tumor treatment, and highlight the revolutionary progress of next-generation CAR-T platforms, especially HLA-independent T cell (HIT) receptor technology, which enables the specific recognition and elimination of CD70 ultra-low expressing tumor cells. Additionally, we summarize the current status of preclinical studies and clinical trials of CD70-targeted CAR-T therapies for solid tumors, including efficacy-enhancing strategies such as epigenetic modulation, combined therapy and gene-edited allogeneic CAR-T cells. In conclusion, CD70 is a paradigm-shifting target for solid tumor immunotherapy, and the development of ultra-sensitive next-generation CAR-T platforms represented by HIT receptors has broken through the key obstacle of targeting CD70 ultra-low expressing cells. The integration of epigenetic diagnostic techniques, high-sensitivity CAR-T cells and rational combination therapy strategies will be the key to realizing the curative potential of CD70-targeted therapy, and this therapy is expected to reshape the treatment landscape of CD70-positive solid tumors, while the translation of these technological breakthroughs still faces challenges such as biomarker development, toxicity management and manufacturing scalability that need to be addressed.
Zitieren
APA
Wang, L. (2025). Targeting CD70 in Solid Tumors: From Epigenetic Heterogeneity to Next-Generation CAR T Cell Therapies. Cancer Immuno Perspectives. https://doi.org/10.70996/cip.00006
Vancouver
Wang L. Targeting CD70 in Solid Tumors: From Epigenetic Heterogeneity to Next-Generation CAR T Cell Therapies. Cancer Immuno Perspectives. 2025. doi:10.70996/cip.00006
BibTeX
@article{Wang2025,
author = {Wang, Lin},
title = {Targeting CD70 in Solid Tumors: From Epigenetic Heterogeneity to Next-Generation CAR T Cell Therapies},
journal = {Cancer Immuno Perspectives},
year = {2025},
doi = {10.70996/cip.00006}
}
EUVIMED